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Abstract 
Background 
We have previously demonstrated in the DIABRISK-SL trial that a trimonthly pragmatic 
lifestyle modification (P-LSM), as compared to a 12-monthly LSM advice (C-LSM), 
significantly reduced the primary composite endpoint of predictors of cardio-metabolic disease 
(new onset type 2 diabetes (T2DM), hypertension, impaired glucose tolerance (IGT), impaired 
fasting glycaemia and markers of cardio-renal disease) in urban participants aged below 40 
years with risk factors for T2DM. 
Main Text 
We now report results of post hoc analyses for those aged below 18 (n = 1725) in three age 
groups, specifically of 6–10 years (P-LSM n = 77, C-LSM n = 59), 10–14 years (P-LSM n = 
534, C-LSM n = 556) and 14–18 years (P-LSM n = 239, C-LSM n = 260). There was no effect 
of P-LSM on the primary endpoint in participants aged below 10 years. Participants aged 10–
14 years in the P-LSM intervention as compared to C-LSM had a lower incidence of the 
primary combined endpoint (87 vs. 106 cases; incident rate ratio (IRR) = 0.85, 95% confidence 
intervals (CI) 0.72–1.01; P = 0.07), driven mainly by the lower incidence of new onset 
hypertension (24 vs. 37 cases; IRR = 0.67, 95% CI 0.49–0.91; P = 0.012). Participants aged 
14–18 years in the P-LSM intervention had a lower incidence of the composite endpoint (36 
vs. 54 cases; IRR = 0.73, 95% CI 0.57–0.94; P = 0.015) as well as a lower incidence of IGT 
(12 vs. 21 cases; IRR = 0.6, 95% CI 0.39–0.92; P = 0.02), new onset hypertension (6 vs. 15 
cases; IRR = 0.43, 95% CI 0.25–0.76; P = 0.004), and new onset dysglycaemia (composite of 
new T2DM, IGT and impaired fasting glycaemia) (30 vs. 46 cases; IRR = 0.74, 95% CI 0.56–
0.97; P = 0.03) compared to those assigned to the C-LSM intervention. Limitations of the 
analyses are the post hoc approach and the small number of events in each group. There were 
no differences in retention between the two groups.  
Conclusions 
Our results suggest that, in young South Asians aged between 10 and 18 years at risk of T2DM, 
a pragmatic lifestyle modification programme may reduce the incidence of predictors of T2DM 
and hypertension. There is a need for further studies in younger populations to evaluate the 
impact and feasibility of interventions to reduce the burden of T2DM and associated cardio-
metabolic risk. 
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Background 
The Prevention of Cardio-metabolic Disease with Lifestyle Modification in Young Urban Sri 
Lankans (DIABRISK-SL) was a randomised controlled clinical trial comparing a trimonthly 
pragmatic lifestyle modification (P-LSM) programme with a less-intensive 12-monthly 
lifestyle modification (C-LSM) programme on a primary composite endpoint of predictors of 
cardio-metabolic disease in young, urban healthy participants aged below 40 years with risk 
factors for T2DM [1]. The study demonstrated the significant impact of a P-LSM programme 
on reducing a primary composite endpoint of predictors of cardio-metabolic disease (new onset 
type 2 diabetes (T2DM), hypertension, impaired glucose tolerance (IGT), impaired fasting 
glycaemia (IFG) and markers of cardio-renal disease) [1].  
We appreciate the interest that Gkioni et al. [2] have shown in our published study by 
highlighting the importance of age differentiation, retention and missing data as factors that 
need to be considered to understand the full potential of the benefits observed in our study. We 
have outlined below the detailed response to each of these factors and the results of further 
analyses are also reported.  
Main Text 
Age differentiation 
Gkioni et al. [2] highlight the importance of further subcategory age differentiation as a factor 
to consider when interpreting the results of the intervention. As detailed in our original 
publication [1], the results for those below the age of 18 were post hoc and thus exploratory, 
and establish the platform and rationale for further studies in this population.  
In response to the comment from Gkioni et al. [2], we have now performed further post hoc 
analyses and report the results of the intervention in age differentiated (6–10 years: P-LSM n 
= 77, C-LSM n = 59; 10–14 years: P-LSM n = 534, C-LSM n = 556; and 14–18 years: P-LSM 
n = 239, C-LSM n = 260) groups for the 1725 participants (P-LSM n = 850, C-LSM n = 875) 
aged below 18 years on the primary cardio-metabolic composite endpoint, new onset 
dysglycaemia (T2DM, IGT, IFG) and selected individual components of the primary 
composite endpoint (Additional file 1: Table S1). Definitions of the endpoints were as 
previously described [1]. 
No effect of P-LSM on cardio-metabolic endpoints was observed in participants aged below 
10 years. There was evidence of a lower incidence of the primary combined endpoint in 
participants in the 10–14 years of age subgroup assigned to the P-LSM group (87 vs. 106 cases; 
incident rate ratio (IRR) = 0.85, 95% confidence intervals (CI) 0.72–1.01; P = 0.07), driven 
mainly by the lower incidence of new onset hypertension in the P-LSM group (24 vs. 37 cases; 
IRR = 0.67, 95% CI 0.49–0.91; P = 0.012) compared to the C-LSM group. Participants in the 
14–18 years of age subgroup assigned to the P-LSM intervention arm had a lower incidence of 
the composite endpoint (36 vs. 54 cases; IRR = 0.73, 95% CI 0.57–0.94; P = 0.015) as well as 
a lower incidence of IGT (12 vs. 21 cases; IRR = 0.6, 95% CI 0.39–0.92; P = 0.02), new onset 
hypertension (6 vs. 15 cases; IRR = 0.43, 95% CI 0.25–0.76; P = 0.004) and new onset 
dysglycaemia (30 vs. 46 cases; IRR = 0.74, 95% CI 0.56–0.97; P = 0.03) compared to those 
assigned to the C-LSM intervention arm. 
These results demonstrate that, in young South Asians at risk of T2DM, a P-LSM programme 
may reduce the incidence of predictors of diabetes and hypertension in those aged 10–18 years. 
As the number of participants in each of these subcategories are modest and the number of 
endpoint events (primary composite and components of the composite endpoint) is low, the 
results of these post hoc results should be considered as exploratory and hypothesis generating. 
Gkioni et al. [2] also raise the point that food choices and activity options may be limited in 
young children and that engagement of their primary carers is key. We agree with this comment 
and, as reported in our original publication, lifestyle modification advice and guidance (which 
was focussed on food choices and detailed exercise options) was also given to the parents of 
younger children (age <16 years) [1].  
Retention and missing data 
There was no impact of retention on the duration of the study. The group-specific median 
duration of follow-up (interquartile range) was 1316 (730–1509) days in P-LSM and 1361 
(806–1504) days in C-LSM (P = 0.5), with no indication of differential retention between 
groups. The number of participants lost to follow-up was also similar between the two groups 
over the duration of the study (P-LSM vs. C-LSM = 110 vs. 114 (year 1), 197 vs. 171 (year 2), 
214 vs. 219 (year 3)).  
The original intention of our study was to follow-up participants for at least 5 years; however, 
as the screening phase (23,298 participants were screened to identify those at risk for potential 
participation, if eligible, in the clinical trial) took longer than originally expected and there 
were restrictions on available resources and funding, the follow-up period was reduced.  
In our original publication, we also reported the baseline features of randomised participants 
(24%) who were not eligible for analyses as they did not attend any visits to receive lifestyle 
advice and we had no follow-up data available on them. These participants had similar baseline 
features as compared to those who were eligible for analyses, but the lack of follow-up 
information is a significant limitation of our work, as acknowledged in our publication [1].  
The primary composite cardio-metabolic endpoint included new onset T2DM, hypertension, 
IGT, IFG, cardiovascular disease and renal disease. The Poisson model was employed for the 
primary analyses as this is suitable when analysing longitudinal data [3, 4]. Poisson regression 
analyses were performed, with person–time as exposure, to estimate the IRR with P-LSM as 
compared to C-LSM. We did not use last observation carried forward or any imputation in the 
primary or secondary key endpoint analyses.  
End of study values for selected clinical and biochemical variables (biomarkers), adjusted for 
baseline value, age and sex for participants above and below 18 years of age in the P-LSM and 
C-LSM groups, were reported in our original manuscript as tables in the additional information 
files [1]. For these biomarker endpoints, the last observation was carried forward for those 
participants with missing endpoint values who did not complete the full duration of the trial.  
As we previously reported [1], at the end of the trial, there was some evidence of lower fasting 
plasma glucose and 2-h post-oral glucose tolerance test plasma glucose levels in the P-LSM 
group compared to the C-LSM group in participants aged above 18 years of age only. Other 
markers, such as blood pressure and anthropometric and lipid parameters, were not different 
between the two groups at the end of the study. In our opinion, the changes in glucose levels 
observed were of modest clinical significance and, as these were not primary endpoints, we do 
not believe further imputation analyses are warranted.  
Conclusion  
As the first randomised controlled trial of its type, in our original manuscript, we openly 
acknowledged the limitations of our study, which were thoroughly addressed therein to the 
satisfaction of the reviewers and the journal editors.  
The results of our exploratory analyses suggest that, in young South Asians aged 10–18 years 
at risk of cardio-metabolic disease, a P-LSM programme may reduce the incidence of 
predictors of T2DM and hypertension. These results highlight the urgent requirement for 
further lifestyle modification studies in younger populations to investigate the impact of the 
intervention(s) on reducing new onset T2DM and associated cardiovascular risk factors.  
DIABRISK-SL is an important first step and useful guide to developing locally applicable 
translation interventions that can address the growing burden of cardio-metabolic disease risk 
in younger persons. 
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